Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04584762
Other study ID # NC05
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 9, 2020
Est. completion date October 31, 2022

Study information

Verified date September 2022
Source Nocira, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, sham-controlled, double-blind study for acute migraine attacks. Randomized to active treatment and sham treatment arms for the first treatment. Optional second active treatment. Follow up at 0, 2 and 24 hours post-treatment.


Description:

Randomized, sham-controlled, double-blind study for acute migraine attacks. Treatment Phase: • ≤60 days to present at clinic for treating up to 2 migraines (at least 48 hours apart). First treatment is randomized between active treatment and sham treatment. Second optional treatment is open-label. Post-Treatment Follow-up Phase: - 24 hours after initiating treatment, for each of up to two migraine treatments, for conducting post-treatment follow-up assessments of migraine symptoms. - 30, 60, and 90 days following the first migraine treatment for migraine diary assessments (and MIDAS assessment at 90 days) Collection of migraine diaries at 30, 60, & 90 days post enrollment. Collection of MIDAS data at 60 and 90 days post treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date October 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. At least 18 years of age at the time of the baseline visit. 2. Episodic migraine with or without aura diagnosed according to the International Classification of Headache Disorders 3 beta diagnostic criteria. 3. Migraine onset before the age of 50 years 4. Migraine present for at least 1 year at the time of the Baseline Visit. 5. Frequency of 1-12 migraine attacks per month in each of the 2 months prior to screening. 6. Willingness, ability, and commitment to participate in baseline and follow-up evaluations without concurrent participation in another clinical trial. 7. Signed patient informed consent form. Exclusion Criteria: 1. Prior or current diagnosis of migraine with brainstem aura, hemiplegic migraine, retinal migraine, migraine aura without headache, vestibular migraine. 2. Use of acute headache medication within previous 48 hours of treatment visit (for each treatment visit). 3. Use of acute medication for headache on >15 days per month in the 3 months prior to the Baseline Visit. 4. Change in migraine preventive therapies or dosage within the preceding 1 month of Baseline Visit. 5. Use of an opioid or barbiturate on more than 4 days per month in each of the 3 months prior to the Baseline Visit. 6. Other primary headache disorder, other than tension-type headache on 3 or fewer days per month. 7. History of secondary non-migraine headache disorders. 8. Medical history of Meniere's disease; endolymphatic hydrops; loss of hearing in either ear that is either complete, requires a hearing aid, or has deteriorated noticeably over the past year; ear surgery (including ear tubes); chronic continuous or current tinnitus; superior canal dehiscence. 9. Discomfort, infection, or other abnormal symptoms or disorders of either ear within 1 month prior to the enrollment Screening or Treatment Visit. 10. Pregnant or trying to become pregnant. 11. Unable to provide informed consent. 12. Inability to present to the medical clinic for study treatment during a migraine attack. 13. Unable or unlikely to follow instructions for proper use of the device. 14. Presence of any condition or state that would prevent the subject from sitting or lying down during the course of the treatment (up to 30 minutes). 15. History of receiving ear pressure therapy (insufflation) to treat any condition. 16. Personal or family affiliation as a service provider (e.g. employee, contractor, consultant, or volunteer) with a migraine treatment device company other than the study sponsor. 17. Perforated or compromised tympanic membrane, and which is confirmed by otoscope inspection by the Investigator before or upon presentation of the subject for the Treatment Visit. 18. Any other information about the subject's medical condition that, in the reasonable professional judgement of the Investigator, may adversely affect the intended safety or results of the treatment as intended and as a reasonable basis to exclude the subject.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Automated Variable Pressure Insufflation
Acute migraine treatment

Locations

Country Name City State
United States StudyMetrix Saint Charles Missouri
United States Murray Chiropractic Neurology Saint Petersburg Florida
United States Regen Pain and Wellness Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Nocira, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Freedom Rates - active Pain freedom rates (PFR) 2 Hours post treatment
See also
  Status Clinical Trial Phase
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Not yet recruiting NCT05943457 - Vitamin K2 Supplementation in Adult Episodic Migraine N/A
Completed NCT01211145 - Zomig - Treatment of Acute Migraine Headache in Adolescents Phase 4
Completed NCT00530517 - A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack Phase 2
Completed NCT00898677 - Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) Phase 3
Recruiting NCT06459635 - Migraine Attack Pain Phase Prediction Study
Completed NCT03971071 - A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache Phase 4
Withdrawn NCT02706015 - Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks Phase 3
Terminated NCT02375789 - Intranasal Cooling for Symptomatic Relief of Migraine N/A
Completed NCT02518464 - Ticagrelor Therapy for RefrACTORy Migraine Study Phase 4
Terminated NCT00391755 - A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches Phase 4
Completed NCT03401346 - Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults Phase 1
Completed NCT05085483 - Ketone for Migraine Prevention N/A
Completed NCT01604785 - Low-dose Propofol for Pediatric Migraine Phase 2/Phase 3
Terminated NCT00804973 - Study in Participants With Acute Migraines Headaches Phase 2
Completed NCT03341689 - Psilocybin for the Treatment of Migraine Headache Phase 1
Completed NCT01630044 - Neurostimulation Device for Treatment of Migraine Headache N/A
Active, not recruiting NCT00285402 - Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine Phase 2
Completed NCT00203255 - Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache N/A
Recruiting NCT06046508 - Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)